Strizek Brigitte, Spicher Theresa, Gottschalk Ingo, Böckenhoff Paul, Simonini Corinna, Berg Christoph, Gembruch Ulrich, Geipel Annegret
Department of Obstetrics and Prenatal Medicine, University Hospital Bonn, Venusberg Campus 1, 53127 Bonn, Germany.
Division of Prenatal Medicine, Department of Obstetrics and Gynecology, University Hospital Cologne, 50937 Cologne, Germany.
J Clin Med. 2022 Apr 22;11(9):2359. doi: 10.3390/jcm11092359.
(1) Background: The aim of this study was to compare perinatal outcomes and complication rates of vesicoamniotic shunting (VAS) before 17 + 0 weeks in isolated LUTO (lower urinary tract obstruction) with the Somatex® intrauterine shunt vs. the Harrison fetal bladder shunt. (2) Methods: This is a retrospective cohort study in two tertiary fetal medicine centers. From 2004−2014, the Harrison fetal bladder shunt was used, and from late 2014−2017, the Somatex shunt. Obstetrics and pediatric charts were reviewed for complications, course of pregnancy, perinatal outcome, and postnatal renal function. (3) Results: Twenty-four fetuses underwent VAS with a Harrison (H) shunt and 33 fetuses with a Somatex (S) shunt. Live birth rates and survival to last follow-up were significantly higher in the Somatex group, at 84.8% and 81.8%, respectively, vs. 50% and 33.3% in the Harrison group (p = 0.007 and p < 0.001). The dislocation rate in the Somatex group (36.4%) was significantly lower than in the Harrison group (87.5%) (p < 0.001). The median time to dislocation was significantly different, at 20.6 days (H) vs. 73.9 days (S) (p = 0.002), as was gestational age at dislocation (17 (H) vs. 25 (S) weeks, p < 0.001). Renal function was normal in early childhood in 51% (S) vs. 29% (H) (p = 0.11). (4) Conclusions: VAS before 17 + 0 weeks gestational age with a Somatex shunt improves perinatal survival significantly and might even have a positive effect on renal function, probably due to the lower dislocation rates. A normal amount of amniotic fluid in the third trimester was the best predictor of normal renal function in early childhood.
(1) 背景:本研究旨在比较17 + 0周之前,索马特克斯®宫内分流器与哈里森胎儿膀胱分流器在孤立性下尿路梗阻(LUTO)中进行羊膜腔分流术(VAS)的围产期结局和并发症发生率。(2) 方法:这是一项在两个三级胎儿医学中心开展的回顾性队列研究。2004年至2014年使用哈里森胎儿膀胱分流器,2014年末至2017年使用索马特克斯分流器。对产科和儿科病历进行回顾,以了解并发症、妊娠过程、围产期结局和产后肾功能情况。(3) 结果:24例胎儿接受了使用哈里森(H)分流器的VAS,33例胎儿接受了使用索马特克斯(S)分流器的VAS。索马特克斯组的活产率和末次随访时的生存率显著更高,分别为84.8%和81.8%,而哈里森组为50%和33.3%(p = 0.007和p < 0.001)。索马特克斯组的移位率(36.4%)显著低于哈里森组(87.5%)(p < 0.001)。移位的中位时间有显著差异,分别为20.6天(H)和73.9天(S)(p = 0.002),移位时的孕周也有差异(17周(H)和25周(S),p < 0.001)。幼儿期肾功能正常的比例在索马特克斯组为51%,在哈里森组为29%(p = 0.11)。(4) 结论:孕龄17 + 0周之前使用索马特克斯分流器进行VAS可显著提高围产期生存率,甚至可能对肾功能有积极影响,这可能是由于移位率较低。孕晚期羊水正常量是幼儿期肾功能正常的最佳预测指标。